Skip to main content
Skip to main content

Peptide Purity Standards: What 95%, 98%, and 99% Really Mean

A practical guide to peptide purity grades, how HPLC measures them, the impurity profiles behind the numbers, and how to verify what a supplier's COA actually claims.

≥95% purity

Research-grade floor. Suitable for in-vitro and preclinical work. Impurity profile becomes hard to characterize below this line.

≥98% purity

GMP / clinical-grade target. Required for injectable pharmaceutical use. USP <1132> impurity limits apply.

≥99% purity

Reference-standard grade. Used for analytical standards and comparator studies. Achievable via preparative HPLC re-purification.

What does peptide purity actually measure?

Purity is a compositional metric determined by reverse-phase HPLC at 214 nm — the wavelength at which the peptide bond absorbs UV light. The instrument separates every molecule in the sample by its interaction with a C18 column, and the detector records a chromatogram showing each species as a distinct peak. The target peptide's peak area, divided by the sum of all peak areas, gives the reported purity percentage.

Common impurities behind the number

  • Deletion sequences — one residue missing from the chain. Common in solid-phase synthesis when a coupling step is incomplete.
  • Truncated sequences — chain terminated early. Usually elute earlier than the target on RP-HPLC.
  • Oxidation products — methionine, cysteine, and tryptophan oxidize during synthesis and storage. Adds +16 Da per oxidation event.
  • Racemization — a residue converted from L- to D-form. Same mass, different biological activity. Hard to detect by mass spec alone.
  • Residual protecting groups — Fmoc, Boc, or side-chain protecting groups not fully cleaved.
  • Trifluoroacetate (TFA) counterion — not an "impurity" per se, but adds mass that isn't active peptide. Ion-exchange to acetate is common for therapeutic grade.

Purity ≠ potency ≠ label accuracy

A vial can be 99% pure and still deliver the wrong dose if the labeled mass is inflated by water content, residual salts, or overfilling. Independent testing verifies three separate things:

  • HPLC purity — what fraction of the sample is target peptide
  • LC-MS identity — confirmation the target peak is actually the intended sequence
  • Karl Fischer water content — how much of the vial mass is water vs peptide

Reading a COA

A legitimate peptide COA is signed, dated, references the batch number, identifies the testing lab, and includes the raw HPLC chromatogram and LC-MS spectrum — not just numbers on a template. If the COA is unsigned, undated, or lacks the underlying chromatograms, treat it as marketing material.

Verifying supplier claims

The only way to know a vial's actual purity is independent testing. Ship a sealed vial from the batch to an independent lab, run HPLC and LC-MS, and compare the result to the supplier's COA. Discrepancies above ±2% purity or any identity failure are grounds to reject the batch.

Peptide Purity Standards FAQ

For research-grade peptides the accepted floor is 95% by HPLC area percent. Therapeutic and GMP-grade peptides target ≥98%. Anything below 95% carries elevated risk of side products, truncated sequences, and unpredictable dosing.

It means 99% of the UV-absorbing peaks on the HPLC chromatogram integrate to the target peptide, with 1% attributable to impurities. It is not a statement about total mass — water, residual salts, and counterions are measured separately by Karl Fischer and elemental analysis.

For most in-vitro and preclinical research, yes. Below 95% the impurity profile becomes hard to characterize and results become harder to reproduce. Long-sequence peptides (>30 residues) often ship at 90-95% because synthesis yield drops with length.

The common ones are deletion sequences (a residue missing), truncated sequences (chain terminated early), oxidation products (methionine, cysteine, tryptophan), racemized residues (D-amino acid contamination), and residual protecting groups. Each shows as a separate peak near the target.

Reverse-phase HPLC with UV detection at 214 nm (the peptide bond wavelength). The area under each peak is integrated; the target peak's percentage of total area is the purity value. LC-MS confirms which peak is the target sequence.

Purity is a compositional measurement (what fraction of the sample is the target molecule). Potency is a functional measurement (how much biological activity the sample produces). A peptide can be 99% pure and still have degraded potency if it has been misfolded or oxidized.

Yes. GMP-grade peptides for injectable pharmaceutical use typically require ≥98% purity, tightly bounded impurity limits per USP <1132>, endotoxin below 0.5 EU/mg, and residual solvent limits per ICH Q3C. Research-grade peptides are not held to these limits.

Purity depends on synthesis method (solid-phase vs solution-phase), cleavage conditions, HPLC purification depth, and QC rigor. Two vials labeled 'semaglutide 10 mg' can range from 62% to 99% pure in independent testing. The label is a claim; a COA from an independent lab is verification.

A document from the testing lab listing every analytical result: HPLC purity chromatogram, LC-MS identity confirmation, molecular weight, water content, residual solvents, endotoxin, and appearance. A legitimate COA is signed, dated, references the batch number, and identifies the testing lab.

Send a sealed vial from the batch to an independent lab for HPLC purity and LC-MS identity testing. Compare the independent result to the supplier COA. Discrepancies above ±2% purity indicate the supplier COA is unreliable.

Verify your supplier's purity claim

Send a sealed vial for independent HPLC purity and LC-MS identity testing. 5-7 business day turnaround from an independent lab.

(561) 513-8435cpierre@acslabtest.com